Goldman Sachs Group Inc C4 Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 880,258 shares of CCCC stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

880,258

Previous 622,720 41.36%

Holding current value

$1.8 Million

Previous $996,000 26.31%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.1 - $1.74 $283,291 - $448,116	257,538 Added 41.36%	880,258 $1.26 Million
Q1 2025 May 09, 2025	BUY	$1.6 - $4.09 $78,504 - $200,675	49,065 Added 8.55%	622,720 $996,000
Q4 2024 Feb 11, 2025	BUY	$3.6 - $7.0 $244,090 - $474,621	67,803 Added 13.4%	573,655 $2.07 Million
Q3 2024 Nov 14, 2024	SELL	$4.43 - $7.38 $1.03 Million - $1.71 Million	-231,983 Reduced 31.44%	505,852 $2.88 Million
Q2 2024 Aug 13, 2024	SELL	$4.05 - $8.1 $2.2 Million - $4.4 Million	-543,407 Reduced 42.41%	737,835 $3.41 Million
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $6.19 Million - $12.8 Million	1,167,729 Added 1028.72%	1,281,242 $10.5 Million
Q4 2023 Feb 13, 2024	SELL	$1.18 - $6.03 $124,147 - $634,416	-105,210 Reduced 48.1%	113,513 $641,000
Q3 2023 May 14, 2024	BUY	$1.81 - $3.89 $190,430 - $409,266	105,210 Added 92.69%	218,723 $406,000
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $21,435 - $46,069	-11,843 Reduced 5.14%	218,723 $406,000
Q2 2023 May 14, 2024	SELL	$2.75 - $3.77 $316,296 - $433,614	-115,017 Reduced 33.28%	230,566 $634,000
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $316,296 - $433,614	-115,017 Reduced 33.28%	230,566 $634,000
Q1 2023 May 14, 2024	BUY	$3.1 - $9.02 $191,056 - $555,911	61,631 Added 21.7%	345,583 $1.09 Million
Q1 2023 May 11, 2023	BUY	$3.1 - $9.02 $191,056 - $555,911	61,631 Added 21.7%	345,583 $1.09 Million
Q4 2022 May 14, 2024	SELL	$5.42 - $10.24 $741,949 - $1.4 Million	-136,891 Reduced 32.53%	283,952 $1.68 Million
Q4 2022 Feb 13, 2023	SELL	$5.42 - $10.24 $741,949 - $1.4 Million	-136,891 Reduced 32.53%	283,952 $1.68 Million
Q3 2022 May 14, 2024	BUY	$8.03 - $12.77 $2.32 Million - $3.69 Million	289,119 Added 219.49%	420,843 $3.69 Million
Q3 2022 Nov 10, 2022	BUY	$8.03 - $12.77 $2.32 Million - $3.69 Million	289,119 Added 219.49%	420,843 $3.69 Million
Q2 2022 May 14, 2024	BUY	$5.06 - $26.46 $92,147 - $481,863	18,211 Added 16.04%	131,724 $993,000
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $60,391 - $315,800	11,935 Added 9.96%	131,724 $993,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $2.1 Million - $3.49 Million	-105,059 Reduced 46.72%	119,789 $2.91 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $1.15 Million - $1.83 Million	-39,116 Reduced 14.82%	224,848 $7.24 Million
Q3 2021 Nov 10, 2021	BUY	$35.91 - $50.5 $9.48 Million - $13.3 Million	263,964 New	263,964 $11.8 Million

Others Institutions Holding CCCC

# of Institutions

103

Shares Held

57.2M

Call Options Held

15.2K

Put Options Held

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $100M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc C4 Therapeutics, Inc. Transaction History